Novel Combination Therapy for Prostate Carcinoma
Abstract
The hypothesis driving this project was validated since an oral DNA vaccine encoding murine VEGF-R2 (FLK-1) induced suppression of angiogenesis and ablation of tumor growth by triggering a specific CTL response specifically killing proliferating endothelial cells - overexpressing FLK-1 in the tumor vasculature. Targeting of genetically stable endothelial cells rather than mutating, heterogeneous tumor cells was achieved in murine models of melanoma, colon and lung carcinoma without impairment in fertility, hematopoiesis and neuromuscular performance and with only a slight decrease in wound healing.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2003
- Accession Number
- ADA417972
Entities
People
- Rong Xiang
Organizations
- Scripps Research